IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
about
Advances in the treatment of newly diagnosed glioblastomaOligodendroglioma: pathology, molecular mechanisms and markersMultidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.Combination genetic signature stratifies lower-grade gliomas better than histological grade.PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patientsIDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas.Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases.A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas.Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse GliomaDiffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers.Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas.Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.The new WHO 2016 classification of brain tumors-what neurosurgeons need to know.Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies.Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.Characterization of gliomas: from morphology to molecules.Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic gliomaPerfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.The role of image-guided intensity modulated proton therapy in glioma.Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status.SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging.Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors.WHO's arrived in 2016! An updated weather forecast for integrated brain tumor diagnosis.Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution.Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.
P2860
Q26773514-05F8CC94-F324-436D-8350-DCF3DE2D4248Q27002448-438FDACF-E78D-4795-9367-A22723848121Q33711322-48A9CE9C-A2BC-4CD9-8DE2-8EF2EF434C5FQ35845197-751F7128-C84E-4076-9952-B0260636679EQ36239445-40DEE326-62EC-4FD6-86E5-A08D335D49F9Q36356194-67BA2F67-7A1E-4EB4-90DB-0C9FA0AD8D37Q36402259-A43A0C0D-E535-4FF3-B08B-60DFF85ACAA7Q36557547-BC530CE3-5432-49EC-B3AC-03588D7A1625Q36569563-2623E470-7DA0-44BE-9F98-94793946688CQ36892843-E5680636-5C74-48D9-B380-8BD0765A159BQ37160414-2388A27A-6535-4470-A8C0-0E58CA9B56D9Q37564326-140AC848-B614-4782-BDBD-9F749BCEB240Q38453759-CEF43C7A-6DB8-459F-9AA6-04BDA2C84A89Q38480437-095B50B9-AA3D-4FFC-8FAE-20715855B01EQ38658533-D4C3F378-B8C7-42D6-B296-282F8A6E01B0Q38870277-8D10AAED-6E76-4A8B-90D4-56C9607126A3Q38940482-636C37F4-9BB9-4E1D-9352-94D84F153C25Q38962177-244240BD-671D-4AC5-BB25-53C4CEEDD85DQ39091307-E29C28E2-7145-4D53-B079-AE4790D4E320Q39159242-08A1DE17-6734-48CF-8A6E-B97DA60AC0E5Q39328886-BC8EA064-3CF2-4E0F-BA4B-41ABF708A7A9Q39412967-08143DE6-0047-4355-B05B-FBAD41001751Q40815536-92D6B4C5-2DF1-4B71-8BE9-F3E80947B346Q40822804-28C6DE1F-49F0-4EE2-A938-543175E3AC94Q41485878-1CC456A0-CB5A-4E63-BD29-E9536A7F42C4Q42178022-F2E43473-AB25-490D-BE25-FC9267E897DAQ45153864-B4AF1633-DB14-44E2-B1C5-BD01A9A602FDQ47566812-143FE353-078C-4BB7-97E8-C4DEF21083E9Q47583690-50EDB2BA-F60B-4FFB-BF0D-265EBD9904E0Q47605895-D19B0438-3A11-4385-BAF8-91CD48082005Q47771695-68325614-A350-4830-8F75-94E8B2409CAFQ47976126-FC4CF753-28DE-4D97-8E4D-F9C1EAD9283CQ48009750-82F25069-4B4F-4E10-BCAA-BC9C7A70FDFBQ48035299-5D5E206E-75E0-4ECD-BC24-C4D32A5CEE52Q48222832-0BD45ED7-7363-463E-9FDF-DA250F46C2D3Q48626706-D4A074F5-D2F5-4663-A368-DA2546421389Q48681045-D8D30F44-FC96-45CA-A16E-9EBA76541CC2Q48841420-D199385B-DDF2-433A-80CE-9033D5DBBCABQ50526883-B6CC8874-0D19-4402-9C25-61EA68982CBDQ52099170-827603BE-08BE-486B-83E4-8B6D23F5C36B
P2860
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
IDH mutation status and role o ...... grade II-III diffuse gliomas.
@ast
IDH mutation status and role o ...... grade II-III diffuse gliomas.
@en
type
label
IDH mutation status and role o ...... grade II-III diffuse gliomas.
@ast
IDH mutation status and role o ...... grade II-III diffuse gliomas.
@en
prefLabel
IDH mutation status and role o ...... grade II-III diffuse gliomas.
@ast
IDH mutation status and role o ...... grade II-III diffuse gliomas.
@en
P2093
P2860
P50
P1476
IDH mutation status and role o ...... grade II-III diffuse gliomas.
@en
P2093
Adriana Olar
Elizabeth Vera-Bolanos
Erik P Sulman
Hinke F van Thuijl
Jaap C Reijneveld
Kenneth D Aldape
Khalida M Wani
Kristin D Alfaro-Munoz
Lindsey E Heathcock
Mark R Gilbert
P2860
P2888
P304
P356
10.1007/S00401-015-1398-Z
P577
2015-02-21T00:00:00Z